Czogalla B, Kahaly M, Mayr D, et al. - Researchers examined nuclear factor erythroid 2-related factor 2 (NRF2) and progesterone receptor A (PRA)/progesterone receptor B (PRB) for their potential prognostic impact in ovarian cancer patients which might be the rationale for putative new treatment strategies. They used immunohistochemistry to determine the presence of NRF2 and PRA/PRB in 156 ovarian cancer samples. Cytoplasmic NRF2 was noted to have a strong correlation with PRA expression and cytoplasmic NRF2 was noted to be strongly correlated with PRB expression. The analysis revealed a longer overall survival (OS) in correlation with cytoplasmic NRF2 expression (median 50.6 vs 32.5 months) as it was seen for PRA expression (median 63.4 vs 33.1 months), although not statistically significant. In addition, they observed a significantly longer OS in association with high PRB expression (median 80.4 vs 32.5 months) and concurrent expression of cytoplasmic NRF2 and PRA (median 109.7 vs 30.6 months). Outcomes thereby support the correlation of the combination of cytoplasmic NRF2 and high PRA/PRB expression with increased OS in ovarian cancer patients.